New

EU–US Innovative Start-ups: From Promise to Scale

How linked bottlenecks shape commercialisation, funding, and expansion

9 chapters139 min total
Keywords
Start-upsScale-upsInnovationCommercialisationVenture capitalPatentsAcquisitionsManagementEcosystemsEU–US
Overview

Using OECD comparisons of start-ups founded between 2000 and 2025 in the EU and US, this series explains why similar innovative activity yields fewer and later advanced outcomes in the EU. It follows linked constraints: formalising and commercialising invention, securing late-stage capital, expanding markets, professionalising management, and connecting ecosystems. The evidence supports a conditional bottleneck model, not one universal lifecycle or causal explanation.

Learning outcomes
  • The EU–US gap widens after early innovation, with fewer and later advanced outcomes in the EU.
  • EU scale-ups patent less often, but patenting firms show comparable or higher recorded invention stocks on average.
  • The clearest financing divergence is late-stage depth for rising superstars, not uniformly weak early funding.
  • Advanced scale depends on combining commercialisation, capital, market reach, management, and ecosystem connections; associations do not prove causation.
Keywords
Start-upsScale-upsInnovationCommercialisationVenture capitalPatentsAcquisitionsManagementEcosystemsEU–US

Chapters

1
13 min
2
16 min
3
18 min
13 min
13 min
14 min
17 min
17 min
18 min

Preview every chapter · Unlock full text, audio, and video from chapter 4

Plans
Ch.1-3 FreeCh.4-9 Premium

FAQ

Where does the EU–US start-up scale-up gap appear?

It appears mainly after the innovative start-up stage: EU shares are lower for growth-oriented firms and rising superstars, and EU firms tend to reach the relevant milestones later.

Does the evidence show that EU start-ups are less innovative than US start-ups?

No. EU scale-ups patent less often, but firms that do patent show comparable or higher recorded invention stocks on average; the evidence instead points to differences in formalisation and commercialisation.

Is the EU–US financing gap mainly about early venture capital?

No. For rising superstars, the clearest divergence appears in later average funding, while early and median trajectories are broadly similar; the upper-tail gap concerns depth and coordination.

What has to happen for an innovative start-up to reach advanced scale?

It must repeatedly convert promise into commercial evidence, deep financing, market reach, organisational capacity, and connected ecosystem support. The articles present this as a conditional model, not a universal lifecycle.

How should readers interpret the OECD scale-up categories?

They are markers of each firm’s highest observed outcome during the sample period, not proof that every start-up passed through the same stages or that the categories show causation.